BioArctic

BioArctic FCF/Debt

The Free Cash Flow to Debt Ratio of BioArctic (BIOA B.ST) as of Oct 8, 2026 is 3,224.01 %. In the previous year, Free Cash Flow to Debt Ratio was -632.45 % — a change of -609.76% (higher).

FCF/Debt

3,224.01 %

YoY

-609.76%

Last updated:

Free Cash Flow to Debt Ratio of BioArctic is 2025 3,224.01 % . Free Cash Flow to Debt Ratio of BioArctic was 2024 -632.45 % . It decreases by -609.76% higher compared to the previous year.

The BioArctic FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
97.70 SEK
Jan 1, 2019
1,183.60 SEK
Jan 1, 2020
-504.69 SEK
Jan 1, 2021
-912.28 SEK
Jan 1, 2022
-442.12 SEK
Jan 1, 2023
6,070.52 SEK
Jan 1, 2024
-632.45 SEK
Jan 1, 2025
3,224.01 SEK
The BioArctic FCF/Debt history
YEARFCF/DebtYoY
3,224.01 %-609.76%
-632.45 %-110.42%
6,070.52 %-1,473.06%
-442.12 %-51.54%
-912.28 %+80.76%
-504.69 %-142.64%
1,183.60 %+1,111.42%
97.70 %+233.23%
29.32 %—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Free Cash Flow to Debt Ratio of BioArctic is 3,224.01 % in 2025.

Free Cash Flow to Debt Ratio of BioArctic changed from -632.45 % to 3,224.01 %, representing a -609.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio BioArctic since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — BioArctic

All Key Metrics — BioArctic